| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $125,000 | 1 | 5 |
Sells | $531,321 | 20 | 95 |
| MCLAUGHLIN KEVIN F | director | 1 | $125,000 | 0 | $0 | $125,000 |
| Allen Robert D. III | Chief Scientific Officer | 0 | $0 | 4 | $87,896 | $-87,896 |
| Duke William E. | Chief Financial Officer | 0 | $0 | 4 | $95,021 | $-95,021 |
| Green Julie | Chief Human Resources Officer | 0 | $0 | 4 | $95,021 | $-95,021 |
| Lee Timothy Edward | Chief Commercial Officer | 0 | $0 | 4 | $95,021 | $-95,021 |
| Andersen Jill | Chief Legal Officer, Secretary | 0 | $0 | 4 | $158,362 | $-158,362 |
Invivyd, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Invivyd maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive …
Over the last 12 months, insiders at Invivyd, Inc. have bought $125,000 and sold $531,321 worth of Invivyd, Inc. stock.
On average, over the past 5 years, insiders at Invivyd, Inc. have bought $125,000 and sold $7.16M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MCLAUGHLIN KEVIN F (director) — $125,000.
The last purchase of 50,000 shares for transaction amount of $125,000 was made by MCLAUGHLIN KEVIN F (director) on 2025‑11‑19.
| 2026-08-18 | Sale | Andersen Jill | Chief Legal Officer, Secretary | 30,706 0.0101% | $0.84 | $25,882 | -7.17% | |
| 2026-08-18 | Sale | Lee Timothy Edward | Chief Commercial Officer | 18,425 0.0061% | $0.84 | $15,530 | -7.17% | |
| 2026-08-18 | Sale | Allen Robert D. III | Chief Scientific Officer | 17,043 0.0056% | $0.84 | $14,366 | -7.17% | |
| 2026-08-18 | Sale | Green Julie | Chief Human Resources Officer | 18,425 0.0061% | $0.84 | $15,530 | -7.17% | |
| 2026-08-18 | Sale | Duke William E. | Chief Financial Officer | 18,425 0.0061% | $0.84 | $15,530 | -7.17% | |
| 2026-08-17 | Sale | Andersen Jill | Chief Legal Officer, Secretary | 37,256 0.0113% | $0.72 | $26,899 | +8.90% | |
| 2026-08-17 | Sale | Lee Timothy Edward | Chief Commercial Officer | 22,355 0.0068% | $0.72 | $16,140 | +8.90% | |
| 2026-08-17 | Sale | Allen Robert D. III | Chief Scientific Officer | 20,679 0.0063% | $0.72 | $14,930 | +8.90% | |
| 2026-08-17 | Sale | Green Julie | Chief Human Resources Officer | 22,355 0.0068% | $0.72 | $16,140 | +8.90% | |
| 2026-08-17 | Sale | Duke William E. | Chief Financial Officer | 22,355 0.0068% | $0.72 | $16,140 | +8.90% | |
| 2026-02-18 | Sale | Andersen Jill | Chief Legal Officer, Secretary | 34,939 0.0252% | $1.58 | $55,127 | -43.11% | |
| 2026-02-18 | Sale | Lee Timothy Edward | Chief Commercial Officer | 20,964 0.0151% | $1.58 | $33,077 | -43.11% | |
| 2026-02-18 | Sale | Allen Robert D. III | Chief Scientific Officer | 19,392 0.014% | $1.58 | $30,597 | -43.11% | |
| 2026-02-18 | Sale | Green Julie | Chief Human Resources Officer | 20,964 0.0151% | $1.58 | $33,077 | -43.11% | |
| 2026-02-18 | Sale | Duke William E. | Chief Financial Officer | 20,964 0.0151% | $1.58 | $33,077 | -43.11% | |
| 2026-02-17 | Sale | Andersen Jill | Chief Legal Officer, Secretary | 32,771 0.0245% | $1.54 | $50,454 | -39.34% | |
| 2026-02-17 | Sale | Lee Timothy Edward | Chief Commercial Officer | 19,663 0.0147% | $1.54 | $30,273 | -39.34% | |
| 2026-02-17 | Sale | Allen Robert D. III | Chief Scientific Officer | 18,189 0.0136% | $1.54 | $28,004 | -39.34% | |
| 2026-02-17 | Sale | Green Julie | Chief Human Resources Officer | 19,663 0.0147% | $1.54 | $30,273 | -39.34% | |
| 2026-02-17 | Sale | Duke William E. | Chief Financial Officer | 19,663 0.0147% | $1.54 | $30,273 | -39.34% |
| Increased Positions | 75 | +97.4% | 115M | +77.1% |
| Decreased Positions | 27 | -35.06% | 13M | -8.44% |
| New Positions | 48 | New | 81M | New |
| Sold Out Positions | 7 | Sold Out | 631,739 | Sold Out |
| Total Postitions | 125 | +62.34% | 251M | +68.66% |
| Janus Henderson Group Plc | $63,458.00 | 9.16% | 25.38M | +25M | New | 2025-09-30 |
| Point72 Asset Management, L.P. | $50,755.00 | 7.33% | 20.3M | +20M | New | 2025-09-30 |
| Maverick Capital Ltd | $47,427.00 | 6.85% | 18.97M | +9M | +85.46% | 2025-09-30 |
| Ra Capital Management, L.P. | $42,798.00 | 6.18% | 17.12M | +17M | New | 2025-09-30 |
| Mithril Ii Gp Lp | $28,104.00 | 4.06% | 11.24M | 0 | 0% | 2025-09-30 |
| Driehaus Capital Management Llc | $25,263.00 | 3.65% | 10.11M | +10M | New | 2025-09-30 |
| M28 Capital Management Lp | $23,121.00 | 3.34% | 9.25M | 0 | 0% | 2025-09-30 |
| Adar1 Capital Management, Llc | $18,427.00 | 2.66% | 7.37M | +7M | New | 2025-09-30 |
| 683 Capital Management, Llc | $15,750.00 | 2.27% | 6.3M | +3M | +105.21% | 2025-09-30 |
| Vanguard Group Inc | $14,407.00 | 2.08% | 5.76M | +2M | +46.72% | 2025-09-30 |